BCIQ Profiles

Company Profile Report
0326 Gyroscope series C
BioCentury & Getty Images


As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

Ophthalmic play could be third gene therapy IPO from Syncona’s portfolio

The ophthalmic play could become the third gene therapy company to go public from Syncona’s portfolio.

Mar 26, 2021 | 10:54 PM GMT


Read the full 522 word article

How to gain access

Continue reading with a
two-week free trial.